Alnylam Pharmaceuticals, Inc.
Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof

Abstract:

The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the programmed cell death 1 ligand 1 (PD-L1) gene, and methods of using such RNAi agents to inhibit expression of a PD-L1 gene and methods of treating subjects having a PD-L1-associated disorder.